3 Small Cap Biotechs Developing Novel Cancer Treatments

Three biotechs with pending clinical catalysts for their experimental cancer treatments.

Feb 18, 2014 at 2:30PM

Cancer drugs can be game-changers for their developers because of their comparatively high margins and their tendency to be applicable to a broad array of disease states. In short, Foolish investors would be wise to keep an eye out for companies developing novel cancer treatments, especially in the small-cap space where a new drug would be a transformative event. So, with this goal in mind, here is my take on three small-cap biotechs with upcoming catalysts for their experimental cancer drugs. 

Inovio could report game-changing mid-stage data soon
Inovio Pharmaceuticals (NASDAQ:INO) is developing a DNA-based vaccine called VGX-3100 with the goal of treating Grade 2/3 Cervical Intraepithelial Neoplasia, or CIN. The vaccine is currently in the midst of a mid-stage trial that is expected to wrap up by the end of March. As such, a topline data readout could come as early as April, but probably no later than May.

Although Inovio hasn't given a precise market projection for VGX-3100, it believes the vaccine's commercial potential lies in the multi-billion dollar range due to the large number of new CIN cases reported each year. This market opportunity dwarfs Inovio's current market cap of $573 million, which is probably why it's one of the most popular small-cap biotechs among retail investors.

What's my take? I personally think speculation has its place in a portfolio, as long as the risk is managed appropriately. With Inovio, it's key to understand that the company is attempting to be the first to commercialize a DNA-based vaccine, which carries its own unique risks. In short, I would caution investors against putting too much into this speculative biotech, but at the same time, the science is compelling enough to warrant a deeper look. 

Insiders buying Merrimack ahead of MM-398's topline data release
Merrimack Pharmaceuticals (NASDAQ:MACK) is a promising developmental stage cancer company that is largely overlooked by the retail community. The company's lead clinical candidate is a liposomal encapsulation of Pfizer's colon cancer drug irinotecan, which Merrimack has dubbed "MM-398." In theory, the liposomal encapsulation should increase absorption of irinotecan into the tumor and allow for higher dosings that increase the drug's clinical benefit.

Merrimack is testing MM-398 in a late-stage trial called NAPOLI-1 as a potential second line treatment for advanced pancreatic cancer. I think Merrimack is worth checking out because topline results for NAPOLI-1 have been pushed back to the second quarter of 2014 due to deaths occurring later than expected.

While management cautioned investors against reading too much into the delay, they did start to buy their own stock in a big way following this announcement. Director Michael Porter, for example, purchased over a million dollars' worth of Merrimack shares on the open market in the fourth quarter of 2013 alone. And he was joined in this insider buying bonanza by both Directors and Officers alike.

While Merrimack does fall firmly under the banner of 'speculative biotech', I believe the recent spate of insider buying, coupled with the delayed data release, makes this company worthy of a deeper look.

Could Sunesis break the trend of small cap cancer drug failures?
A clear trend exists between a company's market cap and the probability of its experimental cancer drug being approved by the FDA. In short, small-cap biotechs have a horrendous track record in terms of approvals for their cancer treatments.

Yet, I think Sunesis Pharmaceuticals (NASDAQ:SNSS) could have what it takes to win one for the little guy. The company's late-stage experimental drug for relapsed and refractory acute myeloid leukemia, or AML, called vosaroxin also had its topline data readout delayed due to deaths occurring later than expected.

What caught my interest was a comment by CEO Daniel Swisher during a presentation at the recent Leerink Global Healthcare Conference in New York. Specifically, he said that patients in the trial "appear to be benefiting from drug therapy". Put simply, the prognosis is so poor for AML that it's hard to imagine that patients are exceeding expectations purely by chance alone.

Why is Sunesis worth checking out? Firstly, management believes vosaroxin's peak sales as an indication for AML could top $1 billion. Moreover, the company has retained worldwide rights to the drug. That said, it's important to understand that the company has less than $50 million in cash, meaning that a secondary offering prior to the data readout is a pretty good bet.

Foolish takeaways
Smallish biotechs that achieve clinical success with a cancer drug tend to be prime buyout targets. And I think all three of these companies could be buyout fodder, if their respective drugs prove successful. Even so, you should always keep the substantial risks of clinical failure in mind, and consider each company's long-term prospects in case things don't go according to plan. With that in mind, I believe Merrimack is the 'safest' play among these three speculative biotechs, but the other two do have intriguing risk to reward ratios, in my opinion, as well. 

An even better stock for your portfolio
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

George Budwell owns shares of Merrimack Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers